Skip to Content
  • Keytruda vs. Opdivo: No Contest

    You don’t always get to see a head-to-head showdown like this one: Merck’s Keytruda (pembrolizumab) and Bristol Myers-Squibb’s Opdivo (nivolum… Read More
  • Pancreatic Cancer Progress? Maybe

    There’s been a vast amount of work (and excitement) in the immunotherapy approaches to cancer in the last few years. Here’s a report on one that I&# Read More
  • Pfizer Buys Medivation

    I wonder how many people have been holding Medivation shares through the years, all the way through? If you have, you must have forgotten that you owned the stu… Read More
  • 3-Bromopyruvate: What a Mess

    There have been several reports of the use of 3-bromopyruvate as an anticancer therapy, despite (as far as I can see) a lack of any controlled human data. Peopl… Read More
  • A Painful Cancer Advertisement

    There’s an op-ed in the New York Times that makes tough reading, and it’s something that we’re going to be seeing more of. The author, Matt J… Read More
  • Opdivo: Euphoria to Panic

    We’ve gotten used to seeing one success after another in the cancer immunotherapy field, so this morning’s news is a bit of a shock: the Bristol-Mye… Read More
Page 4 of 37« First...23456...102030...Last »